bioAffinity Technologies will go public by listing on the NASDAQ on 2 June. The company develops diagnostic tests of lung cancer and other severe early-stage diseases. Let’s take a closer look at bioAffinity Technologies’ business and financial performance.
bioaffinity technologies inc
1 post
are complex instruments and come with a high 
of losing 
rapidly due to 
. 65.68% of retail investor accounts lose 
when trading 
with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high